Market Overview

Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating

Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating
Related BLUE
12 Biggest Mid-Day Losers For Friday
20 Stocks Moving In Friday's Pre-Market Session
Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone (Investor's Business Daily)

Bluebird bio Inc (NASDAQ: BLUE) announced positive early data from its ongoing open-label Phase 1 CRB-401 study with its CAR T candidate, bb2121, in patients with relapsed and/or refractory multiple myeloma.

Although the initial early data is encouraging, there are potential risk of CRS [cytokine release syndrome] at higher doses, Cantor Fitzgerald’s Elemer Piros said in a report.

Piros reiterated a Sell rating on Bluebird, with a price target of $37, commenting that the stock appeared overvalued “based on our valuation of the company's programs.”

Encouraging Myeloma Data

Early results indicated that two of nine patients achieved stringent complete responses [sCR] at a dose of 15x107 cells, encompassing 4-6 months. The initial data improves upon results that had been achieved in a previous study, led by the National Cancer Institute, of a separate anti-BCMA [B-cell maturation antigen] CAR T candidate, Piros stated.

“Safety profile for bb2121 demonstrated no signs of serious Grade 3 neurotoxicities [or CRS] at currently tested doses,” the analyst wrote. “Additional data at later time points and from the high dose of 80x107 “could provide additional clarity on a dose response, but we also remain focused any potential risk of CRS at higher doses.”

Bluebird's product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; and LentiGlobin, which is in clinical studies for the treatment of thalassemia major and severe sickle cell disease.

The stock traded up 26 percent in Thursday's pre-market session.

Latest Ratings for BLUE

Jun 2017Standpoint ResearchDowngradesBuyReduce
Jun 2017BMO CapitalUpgradesMarket PerformOutperform
May 2017Standpoint ResearchInitiates Coverage OnBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Biotech Short Ideas Reiteration Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (BLUE)

View Comments and Join the Discussion!